AI-native biotechnology company developing extrapolative frontier models and an automated design-make-test platform to discover first-in-class small-molecule medicines for validated human disease biology, including targets with no training data
AI-native biotechnology company developing extrapolative frontier models and an automated design-make-test platform to discover first-in-class small-molecule medicines for validated human disease biology, including targets with no training data. Its initial focus is discovering oral alternatives to injectable medicines.